Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506238 | 0.81 | LMNA (0.37) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL4869728 | 0.79 | EPHX1 (0.44) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL300073 | 0.79 | EPHX1 (0.35) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL1155558 | 0.77 | TRPA1 (0.38) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL3748652 | 0.77 | TRPA1 (0.40) | EPHX1CYP1A2ANPEP | |
| SCHEMBL938718 | 0.77 | EPHX1 (0.37) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL406396 | 0.77 | MIF (0.39) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL1461890 | 0.76 | EPHX1 (0.41) | EPHX1CYP1A2 | |
| SCHEMBL3555963 | 0.76 | EPHX1 (0.38) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL1464588 | 0.76 | CTSC (0.36) | EPHX1TAAR1SLC6A2SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| EP-1668014-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | EPHX1 1702/4885TAAR1 180/4885SLC6A2 53/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | EPHX1 1702/4885TAAR1 180/4885SLC6A2 53/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | EPHX1 1702/4885TAAR1 180/4885SLC6A2 53/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | EPHX1 1702/4885TAAR1 180/4885SLC6A2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.